PE20040692A1 - Composiciones oftalmologicas de indazol como bloqueadores de los canales de potasio - Google Patents

Composiciones oftalmologicas de indazol como bloqueadores de los canales de potasio

Info

Publication number
PE20040692A1
PE20040692A1 PE2003001115A PE2003001115A PE20040692A1 PE 20040692 A1 PE20040692 A1 PE 20040692A1 PE 2003001115 A PE2003001115 A PE 2003001115A PE 2003001115 A PE2003001115 A PE 2003001115A PE 20040692 A1 PE20040692 A1 PE 20040692A1
Authority
PE
Peru
Prior art keywords
alkyl
indazol
potassium channels
blockers
compounds
Prior art date
Application number
PE2003001115A
Other languages
English (en)
Inventor
Swaminathan R Natarajan
James B Doherty
Meng-Hsin Chen
Robert M Tynebor
Luping Liu
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of PE20040692A1 publication Critical patent/PE20040692A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503Five-membered rings
    • C07F9/65031Five-membered rings having the nitrogen atoms in the positions 1 and 2
    • C07F9/65038Five-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE INDAZOL DE FORMULA (I) DONDE R Y Ry SON INDEPENDIENTEMENTE H O ALQUIL(C1-C6); R2 ES H, ALQUIL(C1-C10), OH, ALQUENIL(C2-C6), -(CH2)nO(CH2)mOR, -(CH2)nALCOXI(C1-C6), -(CH2)nCICLOALQUILL(C3-C8), ENTRE OTROS; R3 ES H, ALQUIL(C1-C10), -(CH2)nCICLOALQUIL(C3-C8), -(CH2)nO(CH2)mOR, (CH2)nHETEROCICLIL(C3-C10), -(CH2)nCOOR, ENTRE OTROS; R4 Y R5 SON INDEPENDIENTEMENTE H, ALCOXI(C1-C6), OH, ALQUIL(C1-C6), COOR, SOqALQUIL(C1-C6), ENTRE OTROS; R6 ES H, ALQUIL(C1-C10), -(CH2)nARIL(C6-C10), -(CH2)nHETEROCICLIL(C3-C10), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 1-(3-{[6-(2-HIDROXIETIL)PIRIDINA-3-IL]CARBONIL}-6-METOXI-1H-INDAZOL-1-IL)-3,3-DIMETILBUTAN-2-ONA, DI-TER-BUTIL 4-{[1-(3,3-DIMETIL-2-OXOBUTIL)-6-METOXI-1-H-INDAZOL-3-IL]CARBONIL}HIDROXIETILBENCIL; ENTRE OTROS. ESTOS COMPUESTOS SON POTENTES BLOQUEADORES DE LOS CANALES DE POTASIO, ESPECIALMENTE DE LOS CANALES DE POTASIO ACTIVADOS POR CALCIO Y CON ALTA CONDUCTANCIA (MAXI-K), AL BLOQUEARLOS INHIBEN LA PRODUCCION DE HUMOR ACUOSO Y POR ELLO DISMINUYE LA PIO, POR LO QUE SON UTILES PARA EL TRATAMIENTO DE GLAUCOMA Y OTRAS ENFERMEDADES RELACIONADAS CON UNA ELEVADA PRESION INTRAOCULAR.TAMBIEN SE REFIERE A UNA COMPOSICION DEL COMPUESTO CON UNA FORMULACION TOPICA,Y CON OTRO AGENTE ACTIVO COMO UN BLOQUEADOR ß-ADRENERGICO COMO TIMOLOL, BETAXOLOL ENTRE OTROS, UN PARASIMPATICOMIMETICO COMO PILOCARPINA, UN SIMPATICOMIMETICO COMO EPINEFRINA, BRIMONIDINA, UN INHIBIDOR DE LA ANHIDRASA CARBONICA, ENTRE OTROS
PE2003001115A 2002-11-08 2003-11-05 Composiciones oftalmologicas de indazol como bloqueadores de los canales de potasio PE20040692A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42480802P 2002-11-08 2002-11-08
US50009103P 2003-09-04 2003-09-04

Publications (1)

Publication Number Publication Date
PE20040692A1 true PE20040692A1 (es) 2004-10-08

Family

ID=32314559

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003001115A PE20040692A1 (es) 2002-11-08 2003-11-05 Composiciones oftalmologicas de indazol como bloqueadores de los canales de potasio

Country Status (22)

Country Link
US (2) US7196082B2 (es)
EP (1) EP1562909B1 (es)
JP (2) JP4456072B2 (es)
KR (1) KR20050072805A (es)
AR (1) AR041991A1 (es)
AU (2) AU2003286884A1 (es)
BR (1) BR0316040A (es)
CA (1) CA2505086C (es)
CL (1) CL2003002293A1 (es)
DO (1) DOP2003000747A (es)
EC (1) ECSP055781A (es)
HR (1) HRP20050409A2 (es)
IS (1) IS7822A (es)
MA (1) MA27497A1 (es)
MX (1) MXPA05004889A (es)
NO (1) NO20052751D0 (es)
NZ (1) NZ539593A (es)
PE (1) PE20040692A1 (es)
PL (1) PL377172A1 (es)
RU (1) RU2005117627A (es)
TW (1) TWI250873B (es)
WO (2) WO2004043932A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040028469A (ko) 2002-09-30 2004-04-03 엘지전자 주식회사 1 회 기록 가능한 광디스크의 디펙트 영역 관리방법
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
NZ545401A (en) * 2003-09-04 2008-10-31 Merck & Co Inc Ophthalmic compositions for treating ocular hypertension
WO2006020003A2 (en) * 2004-07-20 2006-02-23 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
EP1647549A1 (en) * 2004-10-14 2006-04-19 Laboratoire Theramex Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents
SG175599A1 (en) * 2006-01-31 2011-11-28 Array Biopharma Inc Kinase inhibitors and methods of use thereof
JP2009533326A (ja) * 2006-03-13 2009-09-17 メルク エンド カムパニー インコーポレーテッド 高眼圧症の治療用眼科用組成物
EP2001480A4 (en) * 2006-03-31 2011-06-15 Abbott Lab Indazole CONNECTIONS
EP2352501B1 (en) * 2008-11-03 2014-01-01 ChemoCentryx, Inc. Compounds for use in the treatment of osteoporosis
EP2642998B1 (en) 2010-11-24 2020-09-16 The Trustees of Columbia University in the City of New York A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
US9333202B2 (en) 2012-05-01 2016-05-10 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
ES2700541T3 (es) 2013-03-14 2019-02-18 Univ Columbia Octahidrociclopentapirroles, su preparación y uso
ES2705247T3 (es) 2013-03-14 2019-03-22 Univ Columbia 4-fenilpiperidinas, su preparación y uso
WO2014151959A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
EP4036094A1 (en) 2014-04-30 2022-08-03 The Trustees of Columbia University in the City of New York Substituted 4-phenylpiperidines, their preparation and use
CN104211638A (zh) * 2014-08-13 2014-12-17 李增 一种脂肪氨基取代的芸香碱类衍生物及其制备和作为抗阿尔兹海默症的药物中的应用
EP3402780A1 (en) 2016-01-14 2018-11-21 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2534580A1 (fr) 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
US5151444B1 (en) 1987-09-18 1999-07-06 R Tech Ueno Ltd Ocular hypotensive agents
AU3693789A (en) 1988-05-10 1989-11-29 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) New ophthalmic preparation for treating glaucoma
ES2213504T1 (es) 1988-09-06 2004-09-01 Pfizer Health Ab Derivados de prostaglandina para el tratamiento del glaucoma o hipertension ocular.
US5296504A (en) 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
FR2701026B1 (fr) 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
JP3208210B2 (ja) * 1993-03-17 2001-09-10 旭化成株式会社 結晶性芳香族ポリカーボネートプレポリマーの製造方法及び芳香族ポリカーボネートの製造方法
AU7099194A (en) 1993-06-08 1995-01-03 Vide Pharmaceuticals Methods and compositions for lowering intraocular pressure
US5510383A (en) 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5573758A (en) 1995-04-28 1996-11-12 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
AP2001002304A0 (en) * 1996-05-03 2001-12-31 Pfizer Substituted indazole derivatives and related compounds
US5925342A (en) 1996-11-13 1999-07-20 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
GB2321455A (en) * 1997-01-24 1998-07-29 Norsk Hydro As Lipophilic derivatives of biologically active compounds
EP1114816A4 (en) 1998-09-14 2002-09-04 Ono Pharmaceutical Co SUBSTITUTED PHENYL-PROSTAGLANDIN E DERIVATIVES- $ g (V) AND MEDICINAL PRODUCTS CONTAINING THEM AS ACTIVE INGREDIENT
OA12117A (en) 1999-12-22 2006-05-04 Pfizer Prod Inc EP4 receptor selective agonists in the treatment of osteoporosis.
EP1251862B1 (en) 2000-01-18 2008-10-01 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
WO2001070702A1 (en) 2000-03-17 2001-09-27 Alcon, Inc. 6-hydroxy-indazole derivatives for treating glaucoma
US6956036B1 (en) * 2000-03-17 2005-10-18 Alcon, Inc. 6-hydroxy-indazole derivatives for treating glaucoma
AU2001219180B2 (en) 2000-03-17 2005-04-07 Alcon, Inc. 5-hydroxy indazole derivatives for treating glaucoma
CA2374731A1 (en) 2000-03-31 2001-10-04 Toray Industries, Inc. Agent for modulating growth or generation of hair
WO2002024647A1 (fr) 2000-09-21 2002-03-28 Ono Pharmaceutical Co., Ltd. Agonistes du recepteur de l'ep4 comprenant comme principe actif des derives de la 8-azaprostaglandine
PT1339678E (pt) 2000-11-27 2007-11-30 Pfizer Prod Inc Agonistas selectivos do receptor ep4 no tratamento de osteoporose
FR2827861B1 (fr) 2001-07-27 2004-04-02 Aventis Pharma Sa Derives des indazoles ou des indoles, leur utilisation en medecine humaine et plus particulierement en cancerologie

Also Published As

Publication number Publication date
NO20052751L (no) 2005-06-07
US20040097575A1 (en) 2004-05-20
IS7822A (is) 2005-04-25
JP5061293B2 (ja) 2012-10-31
DOP2003000747A (es) 2004-05-31
TWI250873B (en) 2006-03-11
TW200501949A (en) 2005-01-16
AR041991A1 (es) 2005-06-08
AU2003286884A1 (en) 2004-06-03
JP2010006825A (ja) 2010-01-14
US20070129418A1 (en) 2007-06-07
EP1562909A1 (en) 2005-08-17
MXPA05004889A (es) 2005-07-22
HRP20050409A2 (en) 2006-02-28
JP4456072B2 (ja) 2010-04-28
ECSP055781A (es) 2005-09-20
NO20052751D0 (no) 2005-06-07
CL2003002293A1 (es) 2005-01-14
US7196082B2 (en) 2007-03-27
MA27497A1 (fr) 2005-08-01
NZ539593A (en) 2006-12-22
EP1562909B1 (en) 2012-06-27
AU2003287506A1 (en) 2004-06-03
WO2004043933A1 (en) 2004-05-27
CA2505086A1 (en) 2004-05-27
PL377172A1 (pl) 2006-01-23
US7547720B2 (en) 2009-06-16
AU2003287506B2 (en) 2009-04-23
BR0316040A (pt) 2005-09-13
RU2005117627A (ru) 2006-01-20
WO2004043932A1 (en) 2004-05-27
JP2006508190A (ja) 2006-03-09
KR20050072805A (ko) 2005-07-12
AU2003287506B8 (en) 2009-05-28
CA2505086C (en) 2009-08-25

Similar Documents

Publication Publication Date Title
PE20040692A1 (es) Composiciones oftalmologicas de indazol como bloqueadores de los canales de potasio
PE20050522A1 (es) Derivados de piperidin-2-ona 1,6-disustituida como antagonistas del receptor ep4
HRP20090162T1 (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
NO20074390L (no) Forsterket bimatoprost oye-opplosning
PE20010126A1 (es) Pirrolotriazinas como inhibidores de cinasas
AR087046A2 (es) Compuestos derivados de 4-oxoquinolina
AR033525A1 (es) Arilmetilaminas sustituidas, composiciones farmaceuticas, uso de las mismas para la manufactura de un medicamento
RU2008130111A (ru) (индазол-5-ил)пиразины и (1,3-дигидроиндол-2-он)пиразины для лечения опосредованнызх rно-киназой заболеваний и состояний
CR8505A (es) Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
TN2009000107A1 (en) New sulfonamide derivatives as bradykinin antagonists
PE20050472A1 (es) Formulacion de aerosol que contiene un agente anticolinergico
ECSP055867A (es) Derivados de pirrolopirimidina
PE20060777A1 (es) Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
PE20011184A1 (es) Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa
PE20071132A1 (es) Compuestos macrociclicos como inhibidores del factor viia
NO20071314L (no) Peptidiske vasopressinreseptoragonister
AR066972A1 (es) Derivados azapeptidicos
RU2008142261A (ru) Фармацевтическая композиция с модифицированным высвобождением и ее применение
MA30916B1 (fr) Nouveaux derives de benzamide en tant qu'antagonistes de bradykinine
AR035891A1 (es) Derivados de sulfonamida, un proceso para su produccion, su uso para la fabricacion de un medicamento para el tratamiento o la prevencion de una enfermedad o condicion en donde tenga un papel o este implicada de activacion del receptor de bradiquinina beta1, y composiciones farmaceuticas y combinaci
AR032138A1 (es) Derivados de 6-hidroxi-indazol, una composicion oftalmica, y el uso de dichos derivados para la manufactura de un medicamento para el tratamiento de glaucoma
AR060222A1 (es) Uso de inhibidores de jun quinasas n- terminales para tratar glaucoma
WO2002094796A3 (en) Benzo[g]quinoxaline derivatives as effective compounds against infectious diseases
DE60225143D1 (de) Synergistische pharmazeutische zusammensetzungen zur behandlung bzw. prophylaxe von diabetes
PE20050440A1 (es) Derivados de n-heterociclo sustituidos para modificar la recaptacion de monoaminas

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed